QUA, a leading developer of advanced membrane products for water and wastewater treatment applications, has launched FEDI-Rx Fractional Electrodeionization product range specially designed for applications in pharmaceutical, biomedical and laboratory applications where installations require hot water sanitization to meet pharmacopoeia standards for Purified Water (PW) and Water For Injection (WFI).

Mr VJ Nathan, technical director, QUA Group, said that, "After successful acceptance of our industrial range of FEDI, we are now ready to service the pharma, medical, biomedical, cosmetics and laboratory arena with our innovative product range branded as FEDI-Rx. We are confident that our patented process of manufacturing ion exchange media will provide improved reliability of performance in these applications."

In a short span of two years, the QUA Group's FEDI has more than 25 global installations including various sites in US, Europe and India. The company recently received the 2013 Frost & Sullivan New Product Innovation Award for Industrial Water and Wastewater Treatment Technology, North America, for FEDI electrodeionization and its Q-SEP hollow fiber ultrafiltration modules. Company officials state that India is an important market for the FEDI-Rx fractional electrodeionization product range.

With patented dual voltage technology, QUA's FEDI technology is the next generation of electrodeionization (EDI) technology for the production of high purity water. Developed taking into account the limitations of conventional EDI, the FEDI process improves the reliability of EDI for the production of high purity water.

QUA develops, manufactures and markets advanced membrane products to treat challenging waters. Headquartered in the US, the company also operates facilities in Europe and India.